In summary, MASLD induces a constellation of systemic disturbances—including insulin resistance, chronic inflammation, hormonal imbalances, and gut-derived signals—that collectively create a catabolic environment favoring muscle wasting and bone loss (119). This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.